Why EverydayMeds Offers the Best Wegovy Mounjaro Value
Wegovy vs Mounjaro: UK's Most Competitive Pricing Comparison
When comparing Wegovy and Mounjaro prices across the UK, EverydayMeds consistently offers the most competitive rates for both treatments. Our transparent pricing structure means you know exactly what you're paying upfront, with no hidden consultation fees or prescription charges. Wegovy starts at £79.99 for the 0.25mg starter dose, while our Mounjaro pricing remains equally competitive across all dose strengths. Unlike other providers who separate consultation and medication costs, our prices include everything you need.
The value proposition extends beyond just the medication cost - both Wegovy and Mounjaro require careful dose escalation and ongoing monitoring, which our experienced clinical team provides as part of the service. New customers can apply code FIRST40 at checkout, while returning customers use DOSE25 to access our best rates. This pricing strategy makes both treatments more accessible to patients seeking effective weight management solutions without compromising on clinical standards or pharmaceutical quality.
Comprehensive Wegovy and Mounjaro Bundle Pricing Options
Our bundle pricing for both Wegovy and Mounjaro treatments offers exceptional value for patients planning their weight management journey. Wegovy bundles include our popular Intro Duo (0.25mg & 0.5mg) at £169.99, perfect for the first 8 weeks of treatment, and the Progress Trio (0.5mg, 1mg & 1.7mg) at £369.99 for extended dose escalation. These bundles provide convenience and supply security, eliminating the need for multiple orders during critical early treatment phases.
For patients reaching maintenance doses, our consistency bundles offer steady supply options - such as Consistency 2.4mg (×2) at £419.99 for established Wegovy patients, or the Ultimate Stability Trio (2.4mg ×3) at £649.99 for three months of maintenance supply. Both discount codes FIRST40 and DOSE25 are applied at checkout to reach these final prices, ensuring maximum value whether you're starting Wegovy, Mounjaro, or considering switching between treatments under prescriber guidance.
Clinical Evidence: Wegovy and Mounjaro Effectiveness Data
In clinical trials, patients taking Wegovy alongside diet and exercise achieved remarkable results, with the STEP 1 trial showing approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The STEP 5 trial demonstrated sustained weight loss of approximately 15.2% maintained over 2 years, while the SELECT cardiovascular outcomes trial showed a 20% reduction in major cardiovascular events.
Mounjaro (tirzepatide) clinical trials have shown comparable effectiveness, though direct head-to-head comparisons aren't available due to different trial designs and patient populations. Both treatments work through GLP-1 pathways, with Mounjaro additionally targeting GIP receptors as a dual agonist. The choice between Wegovy and Mounjaro often comes down to individual response, tolerability, and practical considerations like storage requirements rather than efficacy differences.
How Wegovy and Mounjaro Work: Mechanism Comparison
Both Wegovy and Mounjaro are prescription-only medicines that work by mimicking natural hormones involved in appetite regulation and blood sugar control. Wegovy contains semaglutide, a GLP-1 receptor agonist that binds to receptors in the brain's appetite centres, reducing hunger signals and promoting feelings of fullness after smaller meals. This mechanism may also reduce food cravings and slow gastric emptying, helping patients feel satisfied with reduced calorie intake. Mounjaro contains tirzepatide, which targets both GLP-1 and GIP receptors, offering a dual-action approach to weight management. Both treatments require weekly subcutaneous injection and must be used alongside a reduced-calorie diet and increased physical activity to achieve optimal results.
Streamlined Ordering Process for Wegovy and Mounjaro
Getting started with either Wegovy or Mounjaro through EverydayMeds takes just three simple steps, designed for maximum convenience while maintaining clinical safety standards. First, complete our 3-minute online clinical assessment, which covers your medical history, current medications, and weight management goals to help determine suitability for either treatment. Next, our qualified prescribers review your assessment within 3 working days (or 24 hours with express service), evaluating whether Wegovy, Mounjaro, or an alternative approach best suits your needs. Finally, once approved, your medication is dispatched via next-day delivery using temperature-controlled cold-chain logistics to ensure product integrity. Our GPhC-registered pharmacy (#9012878) handles all aspects of supply, from initial assessment through ongoing prescription management and clinical support.
Storage and Practical Considerations: Wegovy vs Mounjaro
Storage requirements represent one key practical difference between Wegovy and Mounjaro that may influence your choice. Both treatments must be stored in the refrigerator at 2-8°C before first use, but Wegovy offers superior travel flexibility with up to 6 weeks of room temperature storage (below 30°C) once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. Both come in pre-filled FlexTouch pens for easy weekly injection, with dose escalation protocols starting from the lowest strength and gradually increasing over 16-20 weeks. Wegovy escalates from 0.25mg through 0.5mg, 1mg, and 1.7mg to the maintenance dose of 2.4mg, while Mounjaro follows its own escalation schedule, with both requiring adherence to prescribed timing to minimise side effects and optimise effectiveness.
UK Market Analysis: Why EverydayMeds Offers Superior Wegovy Mounjaro Value
The UK weight management medication market has seen significant price variation since Wegovy and Mounjaro launched, with some providers charging premium rates for consultation services or splitting costs across multiple transactions. EverydayMeds' approach consolidates all necessary services - clinical assessment, prescriber review, prescription provision, and pharmaceutical supply - into transparent, competitive pricing that consistently ranks among the UK's lowest. Our direct relationships with pharmaceutical distributors and efficient digital-first clinical processes enable us to offer both treatments at prices that make long-term weight management more financially sustainable.
Market analysis shows that hidden costs often inflate the true price of weight management treatments, with some providers charging separately for consultations, prescription fees, and delivery charges. Our all-inclusive pricing model means the advertised price is what you pay, with discount codes FIRST40 and DOSE25 providing additional value for new and returning customers respectively. Both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which treatment aligns best with your clinical needs, lifestyle preferences, and budget considerations.
Start Your Weight Management Journey with Confidence
Whether you choose Wegovy or Mounjaro, starting your weight management journey with EverydayMeds ensures you receive both treatments at the UK's most competitive prices while maintaining the highest clinical and pharmaceutical standards. Apply code FIRST40 at checkout for new customer pricing, or DOSE25 for returning customers, to access our best rates on both treatments. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment today, with expert prescriber guidance available to help you choose between these effective weight management options. Our commitment to transparent pricing, clinical excellence, and patient support makes us the UK's preferred destination for prescription weight management treatments. Both Wegovy and Mounjaro represent significant investments in your health, and our competitive pricing ensures that investment delivers maximum value alongside professional clinical care.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
